Tags

Type your tag names separated by a space and hit enter

Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.
Neurobiol Aging. 2009 Aug; 30(8):1205-16.NA

Abstract

Previous studies have suggested that quetiapine, an atypical antipsychotic drug, may have beneficial effects on cognitive impairment, and be a neuroprotectant in treating neurodegenerative diseases. In the present study, we investigated the effects of quetiapine on memory impairment and pathological changes in an amyloid precursor protein (APP)/presenilin-1 (PS-1) double transgenic mouse model of Alzheimer's disease (AD). Non-transgenic and transgenic mice were treated with quetiapine (0, 2.5, or 5mg/(kg day)) for 1, 4, and 7 months in drinking water from the age of 2 months. After 4 and 7 months of continuous quetiapine administration, memory impairment was prevented, and the number of beta-amyloid (Abeta) plaques decreased in the cortex and hippocampus of the transgenic mice. Quetiapine also decreased brain Abeta peptides, beta-secretase activity and expression, and the level of C99 (an APP C-terminal fragment following cleavage by beta-secretase) in the transgenic mice. Furthermore, quetiapine attenuated anxiety-like behavior, up-regulated cerebral Bcl-2 protein, and decreased cerebral nitrotyrosine in the transgenic mice. These findings suggest that quetiapine can alleviate cognitive impairment and pathological changes in an APP/PS1 double transgenic mouse model of AD, and further indicate that quetiapine may have preventive effects in the treatment of AD.

Authors+Show Affiliations

Laboratory of Neuropharmacology, Wenzhou Medical College, Wenzhou, PR China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18079026

Citation

He, Jue, et al. "Beneficial Effects of Quetiapine in a Transgenic Mouse Model of Alzheimer's Disease." Neurobiology of Aging, vol. 30, no. 8, 2009, pp. 1205-16.
He J, Luo H, Yan B, et al. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging. 2009;30(8):1205-16.
He, J., Luo, H., Yan, B., Yu, Y., Wang, H., Wei, Z., Zhang, Y., Xu, H., Tempier, A., Li, X., & Li, X. M. (2009). Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. Neurobiology of Aging, 30(8), 1205-16.
He J, et al. Beneficial Effects of Quetiapine in a Transgenic Mouse Model of Alzheimer's Disease. Neurobiol Aging. 2009;30(8):1205-16. PubMed PMID: 18079026.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. AU - He,Jue, AU - Luo,Huanmin, AU - Yan,Bin, AU - Yu,Yingxin, AU - Wang,Haitao, AU - Wei,Zelan, AU - Zhang,Yanbo, AU - Xu,Haiyun, AU - Tempier,Adrien, AU - Li,Xiaokun, AU - Li,Xin-Min, Y1 - 2008/02/20/ PY - 2007/05/10/received PY - 2007/10/11/revised PY - 2007/11/02/accepted PY - 2007/12/15/pubmed PY - 2009/9/1/medline PY - 2007/12/15/entrez SP - 1205 EP - 16 JF - Neurobiology of aging JO - Neurobiol Aging VL - 30 IS - 8 N2 - Previous studies have suggested that quetiapine, an atypical antipsychotic drug, may have beneficial effects on cognitive impairment, and be a neuroprotectant in treating neurodegenerative diseases. In the present study, we investigated the effects of quetiapine on memory impairment and pathological changes in an amyloid precursor protein (APP)/presenilin-1 (PS-1) double transgenic mouse model of Alzheimer's disease (AD). Non-transgenic and transgenic mice were treated with quetiapine (0, 2.5, or 5mg/(kg day)) for 1, 4, and 7 months in drinking water from the age of 2 months. After 4 and 7 months of continuous quetiapine administration, memory impairment was prevented, and the number of beta-amyloid (Abeta) plaques decreased in the cortex and hippocampus of the transgenic mice. Quetiapine also decreased brain Abeta peptides, beta-secretase activity and expression, and the level of C99 (an APP C-terminal fragment following cleavage by beta-secretase) in the transgenic mice. Furthermore, quetiapine attenuated anxiety-like behavior, up-regulated cerebral Bcl-2 protein, and decreased cerebral nitrotyrosine in the transgenic mice. These findings suggest that quetiapine can alleviate cognitive impairment and pathological changes in an APP/PS1 double transgenic mouse model of AD, and further indicate that quetiapine may have preventive effects in the treatment of AD. SN - 1558-1497 UR - https://www.unboundmedicine.com/medline/citation/18079026/Beneficial_effects_of_quetiapine_in_a_transgenic_mouse_model_of_Alzheimer's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0197-4580(07)00421-6 DB - PRIME DP - Unbound Medicine ER -